Monsanto

On June 7, 2018, a name disappeared. Bayer AG, having completed its $63 billion acquisition of Monsanto Company, announced that the Monsanto brand would be retired — dissolved, like so much glyphosate into groundwater, into the corporate identity of its German parent. The decision was not sentimental. It was actuarial. By that point, "Monsanto" had become the most reviled corporate name in America, a word that functioned less as a brand than as an epithet — shorthand for everything a certain strain of popular imagination feared about industrial agriculture, genetic manipulation, and the capture of the food system by a single relentless profit-maximizing organism. Protesters dressed as skeletons outside its St. Louis headquarters. Zambia, during a famine in 2002, rejected donated corn rather than accept grain that might contain Monsanto's genetically modified seeds. "Monsatan," the internet called it.

And yet the business that Bayer was absorbing — the actual machine behind the mythologized evil — was, by almost every financial metric that matters, one of the most extraordinary value-creation engines in the history of American agriculture. In its final full fiscal year before the acquisition closed, Monsanto reported $14.6 billion in net sales. Its annualized return on capital over the preceding decade had run around 12%. Its seeds and genomics segment alone generated $10.9 billion in FY2017 revenue, dwarfing every competitor. The company held dominant positions — some would say monopolistic ones — in corn, soybean, and cotton germplasm across the Americas, and its signature herbicide, Roundup, remained the world's most widely used weedkiller despite having gone off patent nearly two decades earlier. Forbes named it Company of the Year in 2009. The market capitalization that Bayer paid to acquire it implied a business worth roughly $128 per share, more than double where it had traded five years prior.

The paradox is the point. Monsanto created enormous economic value and destroyed enormous reputational value, and the two processes were not independent of each other but intimately, structurally linked — the same strategies that built the moat salted the earth around it. Understanding how requires tracing a 117-year arc from a St. Louis chemical startup to the world's most consequential and controversial seed company, through reinventions so radical that the entity Bayer acquired in 2018 shared almost nothing — not a single major product line, not a business model, barely even a molecular focus — with the company that bore the same name in 1960.

The company that would become the world's largest seed producer began with saccharin. John Francis Queeny, a self-educated purchasing agent for a St. Louis drug company, incorporated Monsanto Chemical Works in 1901 — named for his wife, Olga Monsanto Queeny — to manufacture the artificial sweetener for Coca-Cola, which was then still a regional tonic. Queeny had no formal scientific training. What he had was a supplier relationship and the nerve to bet $5,000 of personal savings on an industrial process he'd observed in a German factory. The early years were precarious. Queeny mortgaged his house repeatedly. His son Edgar, who would eventually run the company for decades, grew up in a household where the line between family solvency and corporate solvency did not exist.

This origin matters because it established the template Monsanto would repeat across more than a century: identify a high-value chemical compound, build the manufacturing capability before competitors could scale, defend the position through patent and process innovation, then — when the position eroded — leap to the next molecule. Saccharin gave way to caffeine, vanillin, and aspirin intermediates. By the 1920s Monsanto was a diversified chemical manufacturer. By the 1940s, it was a wartime essential — producing styrene for synthetic rubber, participating in the Manhattan Project's plutonium purification at the Mound Laboratory in Miamisburg, Ohio. The postwar decades brought petrochemicals, plastics, and synthetic fibers. Monsanto manufactured Agent Orange for the U.S. military during Vietnam. It produced polychlorinated biphenyls — PCBs — from the 1930s until they were banned in 1979. It made the laundry detergent All, the artificial turf AstroTurf, and bovine growth hormone.

Each of these product lines generated significant revenue. Each also generated liabilities — environmental, legal, reputational — that accumulated like sedimentary rock beneath the company's balance sheet. The PCB contamination in Anniston, Alabama, where Monsanto operated a production facility for over four decades, would eventually result in a $700 million settlement. Agent Orange lawsuits persisted for decades. The chemical company that John Queeny founded was, by the late twentieth century, carrying the accumulated toxicological and legal baggage of nearly every controversial industrial substance manufactured in America.

This is the context for the most consequential strategic decision in Monsanto's history — and one of the most audacious corporate reinventions in American business.

Around 1979, a decade before the first genetically modified crop would reach a field trial, Monsanto's leadership made a commitment that was, by the standards of mainstream corporate strategy, borderline irrational. The company would invest hundreds of millions of dollars to transform itself from an industrial chemical manufacturer into a biotechnology company.

The instigator was Howard Schneiderman, a Drosophila geneticist from the University of California at Irvine who was recruited to lead Monsanto's corporate research division. Schneiderman had spent his career studying insect development. He had never worked in industry. He was not, by temperament or training, a chemical company man. What he understood — with a clarity that Monsanto's chemical engineers did not — was that the tools of molecular biology, which were then emerging from laboratories at Stanford, UCSF, and Cold Spring Harbor, would eventually permit the precise manipulation of plant genomes in ways that random mutagenesis and selective breeding could not approach. The implications for agriculture were, he believed, existential.

Schneiderman convinced Monsanto's CEO, John Hanley, to invest in a world-class life sciences research center — the Chesterfield Village Research Center outside St. Louis, which opened in 1984 with laboratory facilities that rivaled those of major research universities. Monsanto began funding academic partnerships with Washington University, Harvard, and the Rockefeller University. It recruited molecular biologists at salaries that made chemistry PhDs envious. The research agenda was sweeping: herbicide tolerance, insect resistance, plant genomics, animal health. Monsanto was simultaneously pursuing Bt toxin expression in plants (which would become Bt corn and Bt cotton), glyphosate tolerance in soybeans (which would become Roundup Ready), and bovine somatotropin (which would become Posilac, the recombinant growth hormone for dairy cattle).

The financial logic was straightforward but required an extraordinary tolerance for delayed gratification. Monsanto's chemical businesses were mature. Growth rates were declining. Commodity chemicals competed on price. But a genetically modified seed — a seed carrying a patented gene that conferred a specific, measurable agronomic advantage — was not a commodity. It was intellectual property embedded in a biological delivery system. Every acre planted with that seed would generate a technology fee. Every growing season would create a recurring revenue opportunity. And the switching costs, once a farmer had built an entire cropping system around Roundup Ready soybeans or Bt cotton, would be enormous.

The bet was not without risk. It was, in fact, a bet against the company's own existing identity. As Bart Elmore chronicles in Seed Money: Monsanto's Past and Our Food Future, the transformation required Monsanto to systematically shed the chemical businesses that constituted its historical core — a process that would culminate, under CEO Robert Shapiro in the late 1990s, in a series of spinoffs, mergers, and restructurings so radical that the "new" Monsanto that emerged in 2000 as an independent publicly traded company was, legally and operationally, a different entity from the chemical conglomerate that had preceded it.

No product in agricultural history has generated as much revenue, as much controversy, or as much strategic optionality as Roundup. Glyphosate — the active ingredient — was first synthesized by a Monsanto chemist named John Franz in 1970. It was a broad-spectrum herbicide, meaning it killed virtually all plants it contacted. What made it revolutionary was not its lethality but its mechanism: glyphosate inhibits the enzyme EPSP synthase, which is essential for the shikimic acid pathway in plants. Animals lack this pathway entirely. This meant glyphosate was, relative to other herbicides, remarkably low in mammalian toxicity — a fact that made it attractive to farmers, regulators, and, eventually, suburban homeowners.

Monsanto commercialized Roundup in 1974. By the mid-1990s it had become the company's most profitable product, accounting for roughly 30% of net income by some estimates. But Roundup's U.S. patent was expiring in 2000. Generic competition was inevitable. The standard playbook for a company facing patent expiration on its core product — ask any pharmaceutical executive — is to extend the franchise through reformulation, cut costs, and pray.

Monsanto did something more interesting. It created a biological dependency on the chemical.

Roundup Ready soybeans, the first genetically modified crop approved for commercial planting in the United States, arrived in 1996. The soybeans carried a gene — derived from a strain of Agrobacterium — that encoded a version of EPSP synthase resistant to glyphosate. Plant these seeds, spray your entire field with Roundup, and everything dies except the crop. The elegance was breathtaking. The farmer got weed control that was simpler, cheaper, and more effective than any prior herbicide regime. Monsanto got something far more valuable: a system in which its herbicide and its seeds were complementary goods, each reinforcing demand for the other.

By the time Roundup's patent expired, it didn't matter. The generic herbicide was now a commodity input into a Monsanto-proprietary cropping system. Farmers who planted Roundup Ready seeds needed glyphosate — and even if they bought generic glyphosate, they were still paying Monsanto a technology fee embedded in every bag of seed. Monsanto had transformed a product facing patent cliff into a platform.

Adoption was staggering. By 2005, Roundup Ready soybeans were planted on approximately 87% of U.S. soybean acres. Roundup Ready cotton covered roughly 61% of cotton acres. The seed business was, by this point, eclipsing the herbicide business in strategic importance — but the two remained coupled, a molecular double helix generating revenue from both strands.

Robert Shapiro became Monsanto's CEO in 1995 and immediately set about attempting to transform the company into something unprecedented: a "life sciences" conglomerate that would straddle agriculture, pharmaceuticals, and food — bound together by the common thread of biotechnology. Shapiro was a corporate intellectual, a lawyer by training who spoke about sustainability before it was fashionable and saw in Monsanto's biotech capabilities the potential to address global food security, environmental degradation, and shareholder value simultaneously.

His vision was expansive to the point of recklessness. In a burst of deal-making between 1996 and 1998, Monsanto acquired Holden's Foundation Seeds (the dominant supplier of foundation corn germplasm in the U.S.) for $1.02 billion, DeKalb Genetics for $3.7 billion, and Cargill's international seed operations for $1.4 billion. It bought Asgrow Agronomics, the leading soybean seed brand. It acquired Calgene, which had developed the Flavr Savr tomato. It purchased a 50% stake in the DEKALB Genetics Corporation. This acquisition spree cost billions and was financed partly by the spinoff of Monsanto's chemical businesses into a separate entity called Solutia in 1997.

The strategy had a brutal internal logic: if genetically modified traits were the future of agriculture, the company that controlled the germplasm — the seed genetics into which those traits would be inserted — would control the value chain. Owning Holden's, DeKalb, and Asgrow meant owning the distribution channels through which biotech traits reached farmers. It was the equivalent of buying the record labels after you've invented the MP3.

But Shapiro had miscalculated on two fronts. First, the anti-GMO backlash in Europe was far more ferocious than anyone in St. Louis had anticipated. In 1998, Arpad Pusztai, a researcher at the Rowett Institute in Scotland, went on television claiming that rats fed genetically modified potatoes showed immune system damage. The study was later discredited, but the damage was done. European consumers revolted. Grocery chains pulled GM products from shelves. The European Union imposed a de facto moratorium on new GM crop approvals that would last until 2004. Monsanto's stock, which had risen to the mid-$50s on the life sciences narrative, began to slide.

Second, the acquisition binge had loaded the balance sheet with debt just as the Asian financial crisis and falling crop prices crushed agricultural spending. Monsanto was spending over $1 billion annually on R&D, burning cash on acquisitions it hadn't yet integrated, and facing a revolt from farmers who objected to the premium pricing on its biotech seeds.

By 1999, the "life sciences" strategy was in ruins. Shapiro negotiated a merger with Pharmacia & Upjohn — a pharmaceutical company — that was completed in 2000. The combined entity, Pharmacia Corporation, retained Monsanto's agricultural biotechnology operations as a subsidiary and promptly began divesting them. In October 2000, Pharmacia conducted an IPO of Monsanto shares, raising approximately $700 million. The "new" Monsanto was born — stripped of its pharmaceutical assets, its chemical history legally severed by the Solutia spinoff, and carrying nothing but seeds, herbicides, and the most ambitious biotech pipeline in agriculture.

Shapiro was gone. The company that survived his vision was smaller, more focused, and more vulnerable than at any point in its modern history. It was also, as it would soon prove, more dangerous to competitors than ever before.

The man who rebuilt Monsanto was not the one most people expected. Hugh Grant — not the British actor, a coincidence that generated a lifetime of Google-confusion — was a Scotsman who had joined Monsanto in 1981 as a field salesman and worked his way through international operations, spending years in unglamorous assignments in Southeast Asia and Latin America. He became CEO in 2003, inheriting a company with roughly $4.9 billion in annual revenue, a workforce that had been traumatized by the Pharmacia interlude, and a stock price hovering around $12.

Grant's strategic framework was deceptively simple. Monsanto would be two things: the world's largest seed company and the world's most prolific biotech trait developer. Everything else was noise. He implemented a "pipeline-driven" operating model in which the company's R&D investments were managed with the rigor of a pharmaceutical company's clinical trial program — each trait progressing through defined phases of discovery, proof of concept, regulatory development, and commercial launch, with explicit go/kill decision points and projected peak revenue targets.

The results were extraordinary. Between FY2005 and FY2008, Monsanto's net sales grew from $6.3 billion to $11.4 billion. Net income surged from $255 million to $2.0 billion. The aggregate market value of nonaffiliate common equity, as reported in the company's 10-K filings, rose from approximately $15.7 billion as of February 2005 to approximately $64.0 billion as of February 2008 — a quadrupling in three years.

Grant understood something that Shapiro, for all his intellectual range, had missed: the agricultural biotech business was not a "life sciences" platform. It was a seed franchise with network economics. Every acre of Roundup Ready soybeans planted created social proof for neighboring farms. Every successful growing season with Bt corn reduced the perceived risk of adoption. The technology spread through farming communities the way agricultural practices have always spread — by observation, conversation, and the irrefutable evidence of the neighbor's yield. The network effects were not digital. They were agronomic. But they were real.

Monsanto's business model, as it matured under Grant, functioned as a tollbooth on American agriculture. The company owned patented genetic traits. Those traits were licensed to farmers not through a traditional sale but through a technology use agreement — a legal instrument that specified what farmers could and could not do with the seeds they purchased. They could plant them. They could harvest the crop. They could sell the harvest. But they could not save seed from the harvest for replanting in subsequent seasons. They could not sell seed to their neighbors. They could not conduct their own breeding with Monsanto-trait-containing germplasm.

This represented a fundamental disruption of agricultural tradition. For millennia, farmers had saved seed. The practice was not merely economic; it was cultural, spiritual, deeply embedded in the rhythms of agrarian life. Monsanto's technology agreements extinguished it — converting farmers from independent seed stewards into annual licensees of proprietary genetic material.

The enforcement regime was aggressive to the point of infamy. Monsanto employed a network of investigators — farmers called them the "seed police" — who fanned out across the Midwest, investigating suspected patent violations. The company filed over 140 lawsuits against farmers between 1997 and 2010, alleging unauthorized use of its patented technology. In Monsanto Canada Inc. v. Schmeiser (2004), the Canadian Supreme Court ruled in Monsanto's favor against a Saskatchewan canola farmer, Percy Schmeiser, whose fields contained Roundup Ready canola that he claimed had arrived through wind-blown pollen contamination. The decision established, at least in Canada, that a patent holder's rights extended to seeds containing the patented gene regardless of how they arrived on a farmer's land.

The toll economics were lucrative. By FY2013, Monsanto's Seeds and Genomics segment generated $10.3 billion in net sales on a total company revenue base of $14.9 billion. The gross margin on seed and trait licensing consistently exceeded 50%. And because each new "stacked" trait — combining herbicide tolerance with insect resistance, or multiple modes of insect resistance — commanded a higher technology fee than the single-trait product it replaced, the average revenue per acre planted with Monsanto technology rose steadily over time.

For farmers, the value proposition was real but the power asymmetry was suffocating. Monsanto's traits genuinely improved yields and reduced the need for certain pesticide applications. A 2014 meta-analysis published in PLOS ONE found that GM crop adoption increased yields by an average of 22% and reduced chemical pesticide use by 37%. But the company's pricing power — enabled by its near-monopoly position in key trait markets — captured a large share of the surplus. Between 2000 and 2010, the average price of a bag of soybean seed roughly doubled, and the average price of a bag of corn seed tripled. Farmers were more productive. They were not obviously more profitable.

The genius — and the vulnerability — of Monsanto's position lay in the interplay between two distinct assets: traits and germplasm. Traits were the genetic modifications — Roundup Ready, Bt, drought tolerance — that Monsanto developed in its laboratories. Germplasm was the underlying seed genetics — the inbred lines, hybrids, and varieties that determined a plant's fundamental agronomic characteristics: root strength, ear placement, disease resistance, maturity timing.

Monsanto, through its 1990s acquisition spree, controlled both. It owned DEKALB, Asgrow, Holden's, Seminis (the world's largest vegetable seed company, acquired for $1.4 billion in 2005), and a portfolio of regional seed brands across Latin America, Europe, and Asia. This vertical integration — owning the trait and the seed chassis into which it was inserted — created a structural advantage that competitors could not easily replicate.

Consider the competitive dynamics. DuPont's Pioneer Hi-Bred division was the only corn seed operation with germplasm competitive to Monsanto's DEKALB and Holden's genetics. But Pioneer, for years, licensed Monsanto's biotech traits for insertion into its own germplasm. This created an extraordinary situation: Monsanto's largest competitor in corn seed was simultaneously its largest licensing customer for biotech traits. The tensions implicit in this arrangement erupted into a series of antitrust lawsuits, patent disputes, and licensing negotiations through the 2000s and 2010s — a slow-motion proxy war over the economics of the American corn crop.

The Department of Justice opened an antitrust investigation into Monsanto's seed pricing and licensing practices in 2009. Farmers testified before Congress about market concentration. The investigation was eventually closed without action in 2012, but the reputational damage — Monsanto as monopolist, as Goliath crushing the small farmer — reinforced the narrative that had been building since the seed police controversies of the early 2000s.

The quote, attributed to a Monsanto investigator confronting a country store owner who wasn't even a farmer, encapsulated everything critics found repellant about the company's enforcement posture. Monsanto's response — that it was "simply protecting its patents" and that it invested "more than $2 million a day in research" — was legally defensible and rhetorically tone-deaf. The company consistently failed to understand that its enforcement actions, however justified by patent law, were generating a political and cultural backlash that would eventually find expression in regulatory action, consumer activism, and, ultimately, jury verdicts.

Monsanto's most insidious strategic failure was not operational. It was communicative. The company that mastered the science of genetic modification never mastered the science of narrative.

The anti-GMO movement, which gained significant traction in the late 1990s and early 2000s, was not primarily a scientific dispute. It was a cultural one — about trust, transparency, corporate power, and the relationship between industrial agriculture and the communities that consumed its products. Monsanto met this cultural challenge with the tools of a chemical company: regulatory filings, patent enforcement, and public relations campaigns that treated public skepticism as a problem to be managed rather than a concern to be addressed.

Internal documents that emerged during the Roundup litigation revealed the extent to which this management crossed into manipulation. Monsanto ghostwrote scientific papers defending glyphosate safety and published them under the names of ostensibly independent academics. The company funded organizations like Academics Review — described in a 2010 internal email as a vehicle for "responding to scientific concerns and allegations" while "keeping Monsanto in the background so as not to harm the credibility of the information." It maintained relationships with journalists who amplified pro-Monsanto messaging while compiling dossiers on reporters whose coverage was deemed unfavorable.

None of this was illegal. Most of it was standard corporate communications practice in the pharmaceutical and chemical industries. But the revelation of these tactics — through discovery in the Roundup cancer lawsuits that began reaching juries in 2018 — transformed Monsanto from a controversial company into a confirmed villain in the public imagination. Three separate juries, presented with evidence of the company's internal communications, awarded punitive damages in the hundreds of millions of dollars — not solely because they found that Roundup caused cancer, but because they found that Monsanto had acted with knowing disregard for the possibility.

The irony is that the underlying scientific question — does glyphosate cause cancer in humans? — remained genuinely contested. The International Agency for Research on Cancer classified glyphosate as "probably carcinogenic to humans" in 2015. But the WHO's own joint meeting with the FAO subsequently concluded that glyphosate was "unlikely to pose a carcinogenic risk to humans from exposure through the diet." The U.S. EPA, the European Food Safety Authority, and regulatory agencies in Japan, Canada, and Australia all maintained that glyphosate, used as directed, was safe. The IARC based its assessment partly on epidemiological studies of occupational exposure among agricultural workers — a different question from dietary exposure.

But Monsanto's internal documents undermined the company's ability to participate credibly in this scientific debate. When emails surfaced showing company scientists discussing whether they could "ghost write" safety assessments, the distinction between dietary exposure and occupational exposure — a genuine and important distinction — was lost in the flood of outrage. The messenger had poisoned its own credibility.

Even as the reputational crisis accelerated, the biological one was already advanced. The Roundup Ready system carried within it the seeds — the term is grimly appropriate — of its own obsolescence.

Glyphosate-resistant weeds began appearing in the early 2000s. By 2012, resistant weed species had been identified on tens of millions of U.S. acres. The mechanism was Darwinian and predictable: any herbicide applied with sufficient frequency and uniformity across a sufficiently large land area will select for organisms resistant to it. The more successful Roundup Ready became, the more farmers relied exclusively on glyphosate for weed control, and the faster resistance evolved. Palmer amaranth, waterhemp, marestail, giant ragweed — the list of glyphosate-resistant weeds grew every year.

Monsanto's response was to develop next-generation herbicide tolerance systems. The most significant was the Roundup Ready 2 Xtend system, which combined tolerance to both glyphosate and dicamba — an older herbicide with a broader weed control spectrum. But dicamba had a problem that glyphosate did not: it was volatile. Applied to a field on a warm day, dicamba could vaporize and drift to neighboring fields, damaging crops that were not dicamba-tolerant. Reports of dicamba drift damage surged across the Midwest in 2017. In Arkansas, a farmer was shot and killed in a dispute linked to dicamba drift. Multiple states imposed restrictions on dicamba application timing and formulation.

The situation was a strategic paradox of Monsanto's own creation. The company's dominance had produced a monoculture — not just in the fields but in the weed management paradigm — and monocultures are inherently fragile. The response to that fragility required another proprietary system, which introduced new risks that generated new opposition. The treadmill was biological, economic, and political all at once.

Monsanto's final major strategic initiative before the Bayer acquisition was its push into digital agriculture — specifically, its $930 million acquisition of The Climate Corporation in October 2013. Climate Corp, founded by former Google employees, used machine learning and massive weather datasets to offer crop insurance and, eventually, precision agriculture recommendations to farmers. The thesis was that data about soil conditions, weather patterns, and planting decisions could be combined with Monsanto's proprietary germplasm and trait knowledge to optimize every acre individually — a kind of precision medicine for agriculture.

The acquisition signaled that Monsanto understood its future depended on something beyond molecular biology. Seeds and traits were still the core franchise, but data was the platform upon which the next layer of value — per-acre yield optimization, input cost reduction, and climate risk management — could be built. Climate Corp's platform, rebranded as the Climate FieldView digital agriculture platform, enrolled over 150 million acres of farmland by 2018.

But the competitive dynamics shifted beneath Monsanto's feet. When Bayer agreed to acquire Monsanto in September 2016, the U.S. Department of Justice required Bayer to divest significant assets to BASF — including Bayer's own Liberty herbicide business, its cotton, canola, soybean, and vegetable seed businesses, various R&D projects, and critically, Bayer's own digital agriculture operations. BASF paid $9 billion for the package. The antitrust remedies, designed to preserve competition, had the perverse effect of distributing Monsanto's competitive assets among rivals even as the Monsanto name was being absorbed.

The Bayer-Monsanto merger, which closed on June 7, 2018, was supposed to create the world's largest integrated crop science company. The price — $128 per share, approximately $63 billion in total including debt assumed — represented a 44% premium over Monsanto's pre-announcement share price. Bayer CEO Werner Baumann promised "significant value creation" through combined R&D capabilities, complementary geographic footprints, and the elimination of $1.5 billion in annual cost synergies.

What Baumann got was a litigation liability that would consume the acquirer. Within months of closing, juries in the Roundup cancer cases began returning verdicts against Bayer/Monsanto: $289 million in August 2018 (later reduced to $78 million), $81 million in March 2019, $2 billion in May 2019. By the time Bayer announced a $10.9 billion settlement of the Roundup litigation in June 2020 — covering approximately 95,000 cases — the company's market capitalization had fallen by more than 40% from its pre-acquisition peak. Bayer's shareholders voted against ratifying the management's actions in April 2019 — a nearly unprecedented no-confidence motion in German corporate governance — with the Monsanto acquisition at the center of the revolt.

The activist shareholder Christian Strenger, who led the no-confidence effort, accused Baumann of an "almost complete failure to deliver the key objectives presented" for the Monsanto acquisition. The integration synergies were being realized, but they were invisible beneath the torrent of legal costs and reputational damage. Bayer had purchased not just Monsanto's seed franchise and herbicide portfolio but the accumulated weight of a century of chemical liabilities and two decades of aggressive enforcement culture.

Strip away the controversy, the litigation, the ghostwritten papers, and the seed police, and what remains is a business that accomplished something no other company in the history of agriculture had achieved: it made seeds the primary locus of value in the crop production value chain.

Before Monsanto's biotech revolution, seeds were largely a commodity. Farmers saved them, swapped them, bought them from local dealers at prices that barely covered production costs. Seed companies were regional, fragmented, and operated on thin margins. The intellectual property resided in breeding programs that produced incremental improvements over decades-long cycles.

Monsanto transformed seeds into technology delivery vehicles — carriers of patented genetic information that conferred measurable, field-visible advantages. It built a global germplasm library through acquisition, a biotech trait pipeline through sustained R&D investment (over $1.5 billion annually by the 2010s), and an enforcement and licensing regime that captured the value of its innovations. It proved that biology could be a platform business, that a living organism could function as a software delivery mechanism, and that farmers — the most independent-minded entrepreneurs on the planet — would adopt a recurring-license business model if the value proposition was compelling enough.

The company also demonstrated the limits of that model. Biological systems evolve. Customers who feel captive eventually revolt. Regulatory and legal risks compound over time. And the public — which never really understood the science and was never given sufficient reason to trust the company behind it — ultimately found its voice in the jury box.

On the morning of August 10, 2018, a San Francisco jury found that Monsanto's Roundup had been a "substantial factor" in causing the non-Hodgkin lymphoma of Dewayne "Lee" Johnson, a former school groundskeeper who had used Roundup extensively in his work. The jury awarded $289 million, including $250 million in punitive damages. Johnson, visibly ill in the courtroom, had been given months to live. The Monsanto name — by then already legally absorbed into Bayer — appeared nowhere on the defendant's table. But it was the name the jury heard. It was the name that had become synonymous not just with genetically modified agriculture but with a particular kind of corporate confidence — the belief that if the science was sound, the public would follow; that patents and profits and productivity gains would, in the end, speak for themselves.

The barnacle geese of Svalbard, which Hugh Grant had watched in 2008, kept arriving every May. The timing of the grass bloom kept shifting. The system was, as Grant told Fortune, clearly changing. Whether anyone had the tools to fix it — and whether the tools Monsanto had built were part of the solution or part of the problem — remained, as it had for a century, a question that the data could not conclusively resolve.